Oral GLP-1 FDA approval went from a future possibility to reality twice in four months. For years, GLP-1 therapy meant injections. That has changed.
On December 22, 2025, the FDA approved oral Wegovy 25 mg, a once-daily pill version of semaglutide from Novo Nordisk, making it the first oral GLP-1 receptor agonist approved specifically for weight management. It’s also approved to reduce cardiovascular risk in adults with obesity and established heart disease.
The approval was supported by the OASIS-4 trial, which demonstrated meaningful weight loss as an adjunct to lifestyle changes.
And that was just the start of the oral GLP-1 race. On April 1, 2026, the FDA approved Eli Lilly’s orforglipron, a once-daily oral GLP-1 receptor agonist that is a small molecule rather than a peptide. Unlike oral semaglutide, it can be taken without food or water timing restrictions. In its Phase 3 program, the highest dose produced about 12% average body weight reduction over 72 weeks, versus roughly 1% with placebo.
For researchers studying GLP-1 receptor agonist mechanisms, the shift toward oral delivery opens entirely new questions around bioavailability, dosing kinetics, and adherence that injectable studies couldn’t address. Orforglipron adds another: where peptides still hold the advantage once a non-peptide molecule can reach the same receptor. We cover that question, along with triple agonists and amylin compounds, in next generation GLP-1 peptides. For broader context on how peptides are classified and regulated, see are peptides legal in the United States.
Ongoing FDA enforcement is reshaping how peptides are marketed, sold, and studied across the industry. For deeper context on how the regulatory landscape is evolving, see the FDA peptide reclassification: what actually changed in 2026. For compound-specific research profiles, see the semaglutide research overview, the tirzepatide research overview, and the retatrutide research overview. For a full breakdown of the bioavailability challenges that make oral peptide delivery so difficult and what the research shows on solving them, see oral peptides research: the bioavailability challenge.
To better understand how peptides are classified, studied, and regulated, visit our Research Library.
GLP-1 Pipeline Update: February 2026 — Prime Therapeutics, 2026